Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 13/20 | 0.80 |
| ▸ | THRA | P10827 | 12/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888327 | 0.89 | THRB (1.00) | THRBTHRAPPARGTSHRHSD17B10 | |
| SCHEMBL4890007 | 0.81 | THRB (1.00) | THRBTHRAALDH1A1PPARGHSD17B10 | |
| SCHEMBL4899221 | 0.79 | THRB (1.00) | THRBTHRAALDH1A1PPARG | |
| SCHEMBL4900725 | 0.78 | THRB (1.00) | THRBTHRA | |
| SCHEMBL4898133 | 0.78 | THRB (0.73) | THRBTHRAPPARGTSHRHSD17B10 | |
| SCHEMBL23167605 | 0.77 | PLA2G4B (0.54) | THRBTHRAALDH1A1CYP3A4CA2 | |
| SCHEMBL4887778 | 0.76 | THRB (1.00) | THRBTHRA | |
| SCHEMBL15602736 | 0.72 | PLA2G4B (0.49) | THRBTHRAALDH1A1CYP3A4CA2 | |
| SCHEMBL6702817 | 0.72 | ALDH1A1 (0.51) | THRBTHRAALDH1A1CYP3A4CA2 | |
| SCHEMBL4899348 | 0.72 | THRB (1.00) | THRBTHRAPPARGMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRB 792/4885THRA 559/4885ALDH1A1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.